PMID- 23164159
OWN - NLM
STAT- MEDLINE
DCOM- 20130314
LR  - 20220330
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 155
IP  - 2
DP  - 2013 Feb
TI  - Intravitreal injection of expansile perfluoropropane (c(3)f(8)) for the treatment 
      of vitreomacular traction.
PG  - 270-276.e2
LID - S0002-9394(12)00613-7 [pii]
LID - 10.1016/j.ajo.2012.08.018 [doi]
AB  - PURPOSE: To study the efficacy of a single intravitreal injection of expansile 
      gas in releasing vitreomacular traction. DESIGN: Retrospective, interventional 
      case series. METHODS: Fifteen eyes of 14 consecutive patients with symptomatic 
      and persistent vitreomacular traction (>3 months' duration) on spectral-domain 
      optical coherence tomography (SD OCT) received a single intravitreal injection of 
      0.3 mL 100% perfluoropropane (C(3)F(8)) as an alternative to pars plana 
      vitrectomy (PPV). Primary outcome was the number of eyes with complete 
      vitreomacular traction release on OCT 1 month following treatment. Secondary 
      outcomes included changes in visual acuity (VA), foveal contour, central foveal 
      thickness, and maximal foveal thickness 1 month following treatment, and final 
      VA. RESULTS: Mean age (+/- SD) was 72.1 +/- 12.6 years. Mean follow-up was 398.7 +/- 
      174.4 days. Vitreomacular traction was idiopathic in 7 eyes and associated with 
      diabetes in 6. One month following treatment, vitreomacular traction was released 
      in 6 eyes (40%). Three further eyes (20%) had resolution of vitreomacular 
      traction within 6 months, 4 (27%) underwent PPV, and 2 (13%) subsequently 
      declined surgery. Foveal contour was restored in 7 eyes (47%). VA and central 
      foveal thickness were similar 1 month following treatment, but maximal foveal 
      thickness decreased by 65.8 mum (P = .041). Mean final VA decreased 0.03 logMAR 
      units from baseline (P = .536). Eyes with vitreomacular traction release within 
      1 month had less extensive vitreomacular traction (P = .037), low vitreous face 
      reflectivity, and maximal foveal thickness <500 mum (P = .004) pretreatment. There 
      were no associated adverse events. CONCLUSIONS: Intravitreal C(3)F(8) injection 
      could offer a minimally invasive alternative to PPV in patients with symptomatic 
      and persistent vitreomacular traction. It appears particularly effective in eyes 
      with less extensive vitreomacular traction and low vitreous face reflectivity on 
      SD OCT. Further studies are warranted.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Rodrigues, Ian A
AU  - Rodrigues IA
AD  - Department of Ophthalmology, King's College Hospital, London, United Kingdom.
FAU - Stangos, Alexandros N
AU  - Stangos AN
FAU - McHugh, Dominic A
AU  - McHugh DA
FAU - Jackson, Timothy L
AU  - Jackson TL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121117
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Fluorocarbons)
RN  - CK0N3WH0SR (perflutren)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Eye Diseases/diagnosis/*therapy
MH  - Female
MH  - Fluorocarbons/*administration & dosage/adverse effects
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Pressure
MH  - Retina/pathology
MH  - Retinal Diseases/diagnosis/*therapy
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence
MH  - *Traction
MH  - Treatment Outcome
MH  - Visual Acuity/physiology
MH  - Vitrectomy
MH  - *Vitreous Body
EDAT- 2012/11/21 06:00
MHDA- 2013/03/15 06:00
CRDT- 2012/11/21 06:00
PHST- 2012/06/04 00:00 [received]
PHST- 2012/08/24 00:00 [revised]
PHST- 2012/08/28 00:00 [accepted]
PHST- 2012/11/21 06:00 [entrez]
PHST- 2012/11/21 06:00 [pubmed]
PHST- 2013/03/15 06:00 [medline]
AID - S0002-9394(12)00613-7 [pii]
AID - 10.1016/j.ajo.2012.08.018 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2013 Feb;155(2):270-276.e2. doi: 10.1016/j.ajo.2012.08.018. Epub 
      2012 Nov 17.